Skip to main content

Table 2 Comorbidities and concomitant medication use at baseline in real-world IPF populations receiving nintedanib

From: Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme

Study author, year [reference]

Galli, 2017 [66]

Brunnemer, 2018 [110]

Bonella, 2016 [85]

Barczi, 2019 [67]

Tzouvelekis, 2018 [86]

Kreuter, 2017 [113]

Number of patients

57

64

62

22

94

623

Comorbidities, n (%)

 Arterial hypertension

 

28 (43.8)

19 (31)

14 (63.6)

41 (43.6)

 

 PH

11 (19.3)

5 (7.8)

 

9 (40.9)

16 (17.0)

 

 Congestive heart failure

4 (7)

     

 IHD

14 (24.6)

21 (32.8)

8 (13)

≤5 (22.7)a

20 (21.3)

 

 Diabetes mellitus

15 (26.3)

16 (25)

9 (14.5)

4 (18.2)

18 (19.1)

 

 GERD

31 (54.4)

21 (32.8)

7 (11)

2 (9.1)

38 (40.4)

192 (30.8)

 OSA

 

9 (14.1)

4 (6)

   

 Emphysema

12 (21.1)

9 (14.1)

   

55 (8.8)

 Stroke

 

2 (3.1)

    

Concomitant medications, n (%)

 Prednisone

10 (17.5)

     

 Anti-acid therapy

37 (64.9)

22 (34.4) (PPI)

16 (26) (PPI)

   

 Anticoagulant

7 (12.3)

7 (10.9)

2 (3)

   

 Aspirin + anticoagulant

 

3 (4.7)

    

 N-acetyl cysteine

  

5 (8)

   

 MMF

5 (8.8)

     

 Sildenafil/tadalafil

6 (10.5)

     

 Anti-hypertensive

 

28 (43.8)

19 (31)

   
  1. aIncluded under "cardiovascular diseases" in [67], which also included non-IHD, left heart failure, valvular insufficiency
  2. GERD Gastro-oesophageal reflux disease, IHD Ischaemic heart disease, IPF Idiopathic pulmonary fibrosis, MMF Mycophenolate mofetil, OSA Obstructive sleep apnoea, PH Pulmonary hypertension, PPI Proton pump inhibitor